Reum T, Schäfer U, Marsden C A, Fink H, Morgenstern R
Institute of Pharmacology and Toxicology, Medical Faculty (Charité), Humboldt-University at Berlin, Germany.
Neuropeptides. 1997 Feb;31(1):82-8. doi: 10.1016/s0143-4179(97)90025-1.
Differential pulse voltammetry was used to investigate the extracellular dopamine (DA) and DOPAC signal in the anterior part of nucleus accumbens (N.acc.) after microinjection of cholecystokinin (CCK) derivatives into the ventral tegmental area (VTA). Both the mixed CCK(A)/CCK(B) receptor agonist CCK-8s and the selective CCK(B) receptor agonist CCK-4 caused a dose-dependent increase in the DA signal after doses of 10 ng and 100 ng while CCK-8s had no effect on the DOPAC signal. The CCK(A) receptor antagonist L 364,718 (25 microg/kg i.p.) as well as the CCK(B) receptor antagonist L 365,260 (25 microg/kg i.p.) were administered prior to microinjection of 100 ng CCK-8s and L 365,260, but not L 364,718, completely inhibiting the DA increase produced by CCK-8s. Analysis of the tissue levels of DA and its main metabolites in the anterior part of N.acc. revealed no changes after CCK-8s microapplication into VTA. The presented data indicate a CCK(B) receptor-mediated increase in extracellular DA in the anterior N.acc. after microapplication of CCK derivatives into the VTA.
采用差分脉冲伏安法研究向腹侧被盖区(VTA)微量注射胆囊收缩素(CCK)衍生物后伏隔核前部(N.acc.)的细胞外多巴胺(DA)和3,4-二羟基苯乙酸(DOPAC)信号。混合的CCK(A)/CCK(B)受体激动剂CCK-8s和选择性CCK(B)受体激动剂CCK-4在剂量为10 ng和100 ng时均引起DA信号呈剂量依赖性增加,而CCK-8s对DOPAC信号无影响。在微量注射100 ng CCK-8s之前给予CCK(A)受体拮抗剂L 364,718(25 μg/kg腹腔注射)以及CCK(B)受体拮抗剂L 365,260(25 μg/kg腹腔注射),L 365,260而非L 364,718完全抑制了CCK-8s引起的DA增加。对N.acc.前部的DA及其主要代谢产物的组织水平分析显示,向VTA微量注射CCK-8s后无变化。所呈现的数据表明,向VTA微量注射CCK衍生物后,CCK(B)受体介导N.acc.前部细胞外DA增加。